XIAP
E3 ubiquitin-protein ligase XIAP
As of the edition of 20 October 2026, XIAP (E3 ubiquitin-protein ligase XIAP, UniProt P98170) has 2 drugs tested at it and 4 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P98170
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 74
- Disease areas
- Cancer; Blood and lymph; Digestive system; Heart and blood vessels; Hormones; Immune system; Lungs and airways; Pregnancy and women's health
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| LCL-161 | Stopped | Phase 2 | none listed |
| GDC-0152 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Roche | Route A |
| SCRI Development Innovations | Route A |
| US Oncology | Route A |
The other 1 company at XIAP
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at XIAP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.